Effective treatment of acute hyperkalaemia in childhood by short-term infusion of salbutamol.
Standard
Effective treatment of acute hyperkalaemia in childhood by short-term infusion of salbutamol. / Kemper, Markus J.; Harps, E; Hellwege, H H; Müller-Wiefel, D E.
In: EUR J PEDIATR, Vol. 155, No. 6, 6, 1996, p. 495-497.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Effective treatment of acute hyperkalaemia in childhood by short-term infusion of salbutamol.
AU - Kemper, Markus J.
AU - Harps, E
AU - Hellwege, H H
AU - Müller-Wiefel, D E
PY - 1996
Y1 - 1996
N2 - Hyperkalaemia is a life-threatening emergency and infusion of glucose with insulin has so far been regarded as the standard treatment of choice. Recently the beta-2 stimulatory drug salbutamol has been shown to be an effective agent to treat hyperkalaemia by inducing a shift of potassium into the intracellular compartment. We treated 15 children aged 0.1-14 (mean 5.2) years suffering from acute hyperkalaemia (mean level 6.6 +/- 0.54, range 5.9-7.7 mmol/l) with a single infusion of salbutamol (5 micrograms/kg over 15 min). Serum potassium concentrations decreased significantly within 30 min to levels of 5.74 +/- 0.53 and 4.92 +/- 0.53 mmol/l after 120 min (P < 0.001, respectively). No side-effects occurred other than a light increase in heart rate in 3 patients.
AB - Hyperkalaemia is a life-threatening emergency and infusion of glucose with insulin has so far been regarded as the standard treatment of choice. Recently the beta-2 stimulatory drug salbutamol has been shown to be an effective agent to treat hyperkalaemia by inducing a shift of potassium into the intracellular compartment. We treated 15 children aged 0.1-14 (mean 5.2) years suffering from acute hyperkalaemia (mean level 6.6 +/- 0.54, range 5.9-7.7 mmol/l) with a single infusion of salbutamol (5 micrograms/kg over 15 min). Serum potassium concentrations decreased significantly within 30 min to levels of 5.74 +/- 0.53 and 4.92 +/- 0.53 mmol/l after 120 min (P < 0.001, respectively). No side-effects occurred other than a light increase in heart rate in 3 patients.
KW - Humans
KW - Male
KW - Female
KW - Adolescent
KW - Child
KW - Combined Modality Therapy
KW - Child, Preschool
KW - Infant
KW - Infant, Newborn
KW - Drug Administration Schedule
KW - Infusions, Intravenous
KW - Renal Dialysis
KW - Hyperkalemia/blood/drug therapy/etiology
KW - Potassium/blood
KW - Adrenergic beta-Agonists/administration & dosage
KW - Albuterol/administration & dosage
KW - Peritoneal Dialysis
KW - Humans
KW - Male
KW - Female
KW - Adolescent
KW - Child
KW - Combined Modality Therapy
KW - Child, Preschool
KW - Infant
KW - Infant, Newborn
KW - Drug Administration Schedule
KW - Infusions, Intravenous
KW - Renal Dialysis
KW - Hyperkalemia/blood/drug therapy/etiology
KW - Potassium/blood
KW - Adrenergic beta-Agonists/administration & dosage
KW - Albuterol/administration & dosage
KW - Peritoneal Dialysis
M3 - SCORING: Journal article
VL - 155
SP - 495
EP - 497
JO - EUR J PEDIATR
JF - EUR J PEDIATR
SN - 0340-6199
IS - 6
M1 - 6
ER -